Neurodegenerative focus Target diseases include Alzheimer’s, Parkinson’s and ALS, with a disease-modifying approach addressing underlying protein misfolding pathology. Opportunity for partnerships or co-development on early-stage targets and companion biomarkers.

Clinical-stage traction Proprietary platforms have identified preclinical targets and lead series for Parkinson’s, with ongoing advancement of a Parkinson’s therapy and exploration in Alzheimer’s and ALS. Potential for strategic collaboration, licensing deals, or milestone-driven partnerships.

Funding and grants Significant total funding and grant support, including MJFF grants totaling $1 million and external partnerships, signaling validated science and potential for grant-backed co-development or non-dilutive funding options for partners.

Strategic partnerships Past activity includes a Janssen asset purchase agreement, indicating openness to large pharma collaborations. This could translate into opportunities for asset acquisition, collaboration on research programs, or late-stage co-development.

Small team, agility 11-50 employees with leadership in R&D and finance roles, suggesting nimble decision-making and potential for rapid due diligence. Ideal partner for flexible deal structures, fast-track programs, and tight collaboration timelines.